Insulin resistance, a result of reduced synthesis of prostaglandylinositol cyclic phosphate, a mediator of insulin action? Regulation of cyclic PIP synthetase activity by oral antidiabetic and antihypertensive drugs

Acta Diabetologica

Volumn 34, Issue 4, 1997, Pages 257-264

  Wasner, H K ^a   Salge, U ^a   Psarakis, E ^a   Niktopoulos, A ^a  

^a LEIBNIZ CENTER FOR DIABETES RESEARCH AT HEINRICH HEINE UNIVERSITY DÜSSELDORF   (Germany)

Author keywords

Biguanides; Hypertension; Insulin resistance; Sulfonylureas; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; BIGUANIDE DERIVATIVE; BUFORMIN; CAPTOPRIL; CHLORPROPAMIDE; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; DIHYDRALAZINE; FLUORIDE; GLIBENCLAMIDE; GUANETHIDINE; GUANYLYLIMIDODIPHOSPHATE; INOSITOL PHOSPHATE; INSULIN; METFORMIN; MYOINOSITOL 1 PHOSPHATE SYNTHASE; NORADRENALIN; PHENFORMIN; SERINE; SULFONYLUREA; TOLBUTAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL MEMBRANE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; ESSENTIAL HYPERTENSION; INSULIN RESISTANCE; LIVER CELL; METABOLISM; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SECOND MESSENGER; SPONTANEOUSLY HYPERTENSIVE RAT; TIME;

ANIMALS; ANTIHYPERTENSIVE AGENTS; CARBON-OXYGEN LIGASES; CYCLIC AMP; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DISEASE MODELS, ANIMAL; HYPOGLYCEMIC AGENTS; INOSITOL PHOSPHATES; INSULIN RESISTANCE; LIVER; MALE; MEMBRANE PROTEINS; MICE; PROSTAGLANDINS E; RATS; RATS, INBRED BB; RATS, INBRED SHR; RATS, INBRED WKY; RATS, SPRAGUE-DAWLEY; TIME FACTORS;

EID: 0031439015     PISSN: 09405429     EISSN: None     Source Type: Journal    
DOI: 10.1007/s005920050085     Document Type: Article

References (64)

1. Wasner HK, Salge U, Prostaglandylinositol cyclic phosphate, a second messenger for insulin (abstract). Diabetes Res Clin Pract 1:S595, 1985
2. Psarakis E, Wasner HK, The synthesis of the endogenous cAMP antagonist cPIP is significantly reduced in rat liver plasma membranes of SHR-rats and Ksj db/db mice (abstract). Exp Clin Endocrinol Diabetes 103:A23, 1995
3. Amini H, Wasner HK, The mediator of insulin action, cyclic PIP, is biosynthesized from prostaglandin E and activated inositol polyphosphate in rat liver plasma membranes; regulatory mechanisms controlling the activity of cyclic PIP synthetase (abstract). Exp Clin Endocrinol Diabetes 104(2):A11, 1996
4. Wasner HK, Ammi-Hadi-Kiashar H, Gypakis A, Niktopoulos A, Cyclic PIP synthetase, activated by tyrosine phosphorylation, combines prostaglandin E with activated inositol phosphate to cyclic PIP, a mediator of insulin action (abstract). Exp Clin Endocrinol Diabetes 104 [Suppl 2]:142, 1996
5. Olefsky JM, Molina JM, Insulin resistance in man. In: Rifkin H, Porte D (eds) Diabetes mellitus. Theory and practice, 4th edn. Elsevier, New York, pp 121-153, 1990
6. DeFronzo R, The triumvirate: β-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 37:667-687, 1988
7. Saltiel AR, Fox JA, Sherline P, Cuatrecasas P, Insulin-stimulated hydrolysis of a novel glycolipid generates modulators of cAMP phosphodiesterase. Science 233:967-972, 1986
8. Saltiel AR, Cuatrecasas P, In search of a second messenger for insulin. Am J Physiol 255 (Cell Physiol 24):C1-C11, 1988
9. Alvarez JF, Varely I, Ruiz-Albusac JM, Mato JM, Localisation of the insulin-sensitive phosphatidylinositol glycan at the outer surface of the cell membrane, Biochem Biophys Res Commun 152:1455-1462, 1988
10. Kennington AS, Hill CR, Craig BA, Bogardus C, Raz I, Ortmeyer HK, Hansen BC, Romero G, Larner J, Low urinary chiro-inositol excretion in non-insulin-dependent diabetes mellitus. N Engl J Med 323:373-378, 1990
11. Asplin I, Galasko G, Larner J, Chiro-inositol deficiency and insulin resistance: a comparison of the chiro-inositol- and the myo-inositol-containing insulin mediators isolated from urine, hemodialysate, and muscle of control and type II diabetic subjects. Proc Natl Acad Sci USA 90:5924-5928, 1993
12. Macaulay SL, Larkins RG, Impaired insulin action in adipocytes of New Zealand obese mice: a role for postbinding defects in pyruvate dehydrogenase and insulin mediator activity. Metabolism 37:958-965, 1988
13. Macaulay SL, Clark S, Larkins RG, Correlation of insulin receptor level with both insulin action and breakdown of a potential insulin mediator precursor: studies in CHO cell-lines transfected with insulin receptor cDNA. Biochim Biophys Acta 1134:53-60, 1992
14. Sanchez-Arias JA, Sanchez-Gutierrez JC, Guadano A, Alvarez JF, Samper B, Mato JM, Feliu JE, Impairment of glycosyl-phosphatidylinositol-dependent insulin signaling system in isolated rat hepatocytes by streptozotocin-induced diabetes. Endocrinology 131:1727-1733, 1992
15. Wasner HK, Regulation of protein kinase and phosphoprotein phosphatase by cyclic AMP and cyclic AMP antagonist. FEBS Lett 57:60-63, 1975
16. Wasner HK, Biosynthesis of cyclic AMP antagonist in hepatocytes from rats after adrenalin- or insulin-stimulation (isolation, purification and prostaglandin E requirement for its synthesis). FEBS Lett 133:260-264, 1981
17. Partke HJ, Wasner HK, Cyclic AMP antagonist, a second messenger for insulin action, inhibits glucose-stimulated insulin secretion in isolated islets of Chinese hamsters. In: Atwater I, Rojas E, Soria D (eds) Biophysics of the pancreatic β-cell. Plenum, New York, pp 409-412, 1987
18. Wasner HK, Lemoine H, Junger E, Leßmann M, Kaufmann R, Prostaglandylinositol cyclic phosphate, a new second messenger. In: Bailey JM (ed) Prostagtandins, leukotrienes, lipoxins and PAF. Plenum, New York, pp 153-168, 1991
19. Wasner HK, Kaufmann R, Lemoine H, Mass spectrometric identification of prostaglandylinositol, the dephosphorylated cyclic AMP antagonist, cyclic PIP. Analusis 20:171-177, 1992
20. Wasner HK, Salge U, Gebel M, The endogenous cyclic AMP antagonist, cyclic PIP: its ubiquity, hormone stimulated synthesis and identification as prostaglandylinositol cyclic phosphate. Acta Diabetol 30:220-232, 1993
21. Wasner HK, Weber S, Partke HJ, Amini-Hadi-Kiashar H, Indomethacin treatment causes loss of insulin action in rats: involvement of prostaglandins in the mechanism of insulin action. Acta Diabetol 31:175-182, 1994
22. Wasner HK, Leßmann M, Conrad M, Amini H, Psarakis E, Mir-Mohammad-Sadegh A, Biosynthesis of the endogenous cyclic adenosine monophosphate (AMP) antagonist, prostaglandylinositol cyclic phosphate (cyclic PIP), from prostaglandin E and activated inositol polyphosphate in rat liver plasma membranes. Acta Diabetol 33:126-138, 1996
23. Gypakis A, Amini-Hadi-Kiashar H, Wasner HK, The endogenous cAMP antagonist cPIP is biosynthesized from prostaglandin E and guanosine diphosphate inositol phosphate (abstract). Exp Clin Endocrinol Diabetes 103:A16, 1995
24. Robison GA, Butcher RW, Sutherland EW, Cyclic AMP. Academic Press, New York, pp 271-284, 1971
25. Chiappe De Cingolani GE, β-Adrenergic receptors and adenylate cyclase activity in diabetic rat fat cells. Diabetes 35:1229-1232, 1986
26. Wasner HK, Amini H, Gypakis A, Psarakis E, Biosynthesis and action of the endogenous cAMP antagonist cPIP (abstract). 9th International Conference of Second Messengers & Phosphoproteins, Tenn., USA 1995, abstract 101
27. Duhault J, Lavielle R, History and evolution of the concept of oral therapy in diabetes. Diabetes Res Clin Pract 14:S9-S14, 1991
28. Bailey CJ, Metformin revisited: its actions and indications for use (review). Diabetic Med 5:315-320, 1988
29. Krentz AJ, Ferner RE, Bailey CJ, Comparative tolerability profiles of oral antidiabetic agents. Drug Safety 11:223-241, 1994
30. Marena S, Tagliaferro V, Montegrosso G, Pagano A, Scaglione L, Pagano G, Metabolic effects of metformin addition to chronic glibenclamide treatment in type 2 diabetes. Diabete Metab 20:15-19, 1994
31. Slama G, The insulin sparing effect of metformin in insulin-treated diabetic patients. Diabete Metab 17:241-243, 1991
32. Bailey CJ, Biguanides and NIDDM. Diabetes Care 15:755-772, 1992
33. Hotta N, Komori T, Lobayashi M, Sakakibara F, Koh N, Sakamoto N, The inhibitory action of buformin, a biguanide on gluconeogenesis from alanine and its transport system in rat livers. Diabetes Res Clin Pract 19:49-58, 1993
34. Park DJ, Min HK, Rhee SG, Inhibition of CD3-linked phospholipase C by phorbol ester and by cyclic AMP is associated with decreased phosphotyrosine and increased phosphoserine contents of PLC-gamma-1. J Biol Chem 267:1496-1501, 1992
35. Kahn CR, Banting lecture. Insulin action, diabetogenes, and the cause of type II diabetes. Diabetes 43:1066-1084, 1994
36. Kahn CR, Vicent D, Doria A, Genetics of non-insulin-dependent (type II) diabetes mellitus. Annu Rev Med 47:509-531, 1996
37. Brüning JC, Winnay J, Bonner-Weir S, Taylor SI, Accili D, Kahn CR, Development of a novel polygenic model of NIDDM in mice heterozygous for IR and IRS-1 null alleles. Cell 88:561-572, 1997
38. Amini H, Wasner HK, Cyclic PIP, a mediator of insulin action and cPIP synthetase activated by antidiabetic and antihypertensive drugs. Exp Clin Endocrinol Diabetes 104(6):A13, 1996
39. Folh F, Saad MJA, Kahn CR, Insulin receptor/IRS-1/PI 3-kinase signaling system in corticosteroid-induced insulin resistance. Acta Diabetol 33:185-192, 1996
40. Buffington CK, Pourmotabbed G, Kitabchi AE, Case report: amelioration of insulin resistance in diabetes with dehydroepiandrosterone. Am J Med Sci 306:320-324, 1993
41. Birkeland KI, Hanssen KF, Torjensen PA, Vaaler S, Level of sex hormone-binding globulin is positively correlated with insulin sensitivity in men with type 2 diabetes. J Clin Endocrinol Metab 76:275-278, 1993
42. 2 activity in plasma and liver in uncontrolled diabetes mellitus. Diabetes 35:403-410, 1986
43. Brenner R, Peluffo RO, Mercuri O, Restelli M, Effect of arachidonic acid in the alloxan-diabetic rat. Am J Physiol 215:63-70, 1968
44. Holman RT, Johnson SB, Gerrard JM, Mauer SM, Kupcho-Sandberg S, Brown DM, Arachidonic acid deficiency in streptozotocin-induced diabetes. Proc Natl Acad Sci USA 80:2375-2379, 1983
45. Greene DA, De Jesus PV, Winegrad AI, Effects of insulin and dietary myo-inositol on impaired peripheral motor nerve conduction velocity in acute streptozotocin diabetes. J Clin Invest 55:1326-1336, 1975
46. Greene DA, Lattimer SA, Impaired rat sciatic nerve sodium-potassium adenosine triphosphatase in acute streptozotocin diabetes and its correction by dietary myo-inositol supplementation. J Clin Invest 72:1058-1063, 1983
47. Berti-Mattera L, Day N, Peterson RG, Eichberg J, An aldose reductase inhibitor but not myo-inositol blocks enhanced polyphosphoinositide turnover in peripheral nerve from diabetic rats. Metabolism 45:320-327, 1996
48. Goraya TY, Wilkins P, Douglas JG, Zhou J, Berti-Mattera LN, Signal transduction alterations in peripheral nerves from streptozotocin-induced diabetic rats. J Neurosci Res 41:518-525, 1995
49. Tokuyama Y, Fan Z, Furuta H, Makielski JC, Polonsky KS, Bell GI, Yano H, Rat inwardly rectifying potassium channel Kir6.2: cloning electrophysiological characterization, and decreased expression in pancreatic islets of male Zucker diabetic fatty rats. Biochem Biophys Res Commun 220:532-538, 1996
50. Dominguez L, Davidoff A, Srinivas P, Standley P, Walsh M, Sowers J, Effects of metformin on tyrosine kinase activity, glucose transport, and intracellular calcium in rat vascular smooth muscle. Endocrinology 137:113-121, 1996
51. Ferrannini E, Buzzigoli G, Bonadonna R, Giorico MA, Oleggini M, Graziadei L, Pedrinelli R, Brandi L, Bevilacqua S, Insulin resistance in essential hypertension. N Engl J Med 317: 350-357, 1987
52. Fun M, Shieh SM, Wu DA, Chen YD, Reaven GM, Abnormalities of carbohydrate and lipid metabolism in patients with hypertension. Arch Intern Med 147:1035-1038, 1987
53. Pollare T, Lithell H, Berne C, Insulin resistance is a characteristic feature of primary hypertension independent of obesity. Metabolism 39:167-174, 1990
54. 2 inhibits and indomethacin enhances noradrenaline release in isolated kidneys of adult spontaneously hypertensive rats. Br J Clin Pharmacol 30 [Suppl 1]:165S-167S, 1990
55. Takata Y, Mochizuki S, Kato H, Effect of chronically administered hydralazine on altered adrenergic neurotransmission mediated by presynaptic alpha- and beta-adrenoceptors in spontaneously hypertensive rats. J Pharmacobiodyn 13:565-573, 1990
56. Tsuda K, Masuyama Y, Inhibition of norepinephrine release from vascular adrenergic neurons by oral administration of beta-blocker in DOCA sait hypertension. Am J Hypertens 4:68-71, 1991
57. Ferrier C, Jennings GL, Eisenhofer G, Lambert G, Cox HS, Kalff V, Kelly M, Esler MD, Evidence for increased noradrenaline release from subcortical brain regions in essential hypertension. J Hypertens 11:1217-1227, 1993
58. Pacak K, Yadid G, Jakob G, Lenders JW, Kopin IJ, Goldstein DS, In vivo hypothalamic release and synthesis of catecholamines in spontaneously hypertensive rats. Hypertension 22: 467-478, 1993
59. Lembo G, Rendina V, Iaccarino G, Lamenza F, Volpe M, Trimarco B, Insulin reduces reflex forearm sympathetic vasoconstriction in healthy humans. Hypertension 21:1015-1019, 1993
60. Sato T, Nara Y, Kato Y, Yamori Y, Effect of antihypertensive treatment with alacepril on insulin resistance in diabetic spontaneously hypertensive rats. Metabolism 45:457-462, 1996
61. Lind L, Pollare T, Berne C, Lithell H, Long-term metabolic effects of antihypertensive drugs. Am Heart J 128:1177-1183, 1994
62. Paolisso G, Gambardella A, Verza M, D'Amore A, Sgambato S, Varricchio M, ACE inhibition improves insulin-sensitivity in aged insulin-resistant hypertensive patients. J Hum Hypertens 6:175-179, 1992
63. Verma S, Bhanot S, McNeill J, Decreased vascular reactivity in metformin-treated fructose-hypertensive rats. Metabolism 45. 1053-1055, 1996
64. Giugliano D, De-Rosa N, Di-Maro G, Marfella R, Acampora R, Buoninconti R, D'Onofrio F, Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women. Diabetes Care 16:1387-1390, 1993